Biomarker for Sly Disease (MPS VII) (BioSly)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-20

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

NCT02298686

Mental Retardation Developmental Delay

WITHDRAWN

Biomarker for Mannosidosis Disease (BioMannosidosis)

NCT03264040

Alpha-Mannosidase B Deficiency Lysosomal Alpha B Mannosidosis Alpha-Mannosidase Deficiency

WITHDRAWN

Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)

NCT02837523

Renal Fanconi Syndrome Photophobia Hypophosphatemia

WITHDRAWN

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

NCT00299000

Mucopolysaccharidosis VI Maroteaux-Lamy Syndrome

COMPLETED PHASE4

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

NCT00214773

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mucopolysaccharidosis type VII (also known as Sly syndrome or Sly disease) is an inherited disease caused by a lack of the enzyme beta-glucuronidase. This enzyme is needed to break down substances in the body called glycosaminoglycans (GAGs). If the enzyme is not present, GAGs cannot be broken down and they build up in the cells and damage them. This causes a wide range of problems such as short stature, skeletal abnormalities, joint stiffness, enlarged spleen and liver, lung infections, heart problems and hernias. Patients usually die within the first year of life, although some survive into their teenage years.

Mucopolysaccharidosis type VII is a life-threatening disease with many patients dying in early childhood. It also debilitating due to the physical and skeletal abnormalities that occur.

Sly syndrome is characterized by coarse facial features, hepatosplenomegaly, protruding sternum and dystosis multiplex. Dystosis multiplex refers to a constellation of skeletal abnormalities and is characterized by an enlarged skull, thickened calvarium, premature closure of lamboid and sagittal sutures, shallow orbits, enlarged J-shaped sella and abnormal spacing of the teeth with dentigerous cysts. There is anterior hypoplasia of the lumbar vertebrae, the long bone diaphyses are enlarged and an irregular appearance of the metaphyses. The epiphyseal centers not well developed, the pelvis is poorly formed with small femoral heads and coxa valga. The clavicles are short, thick and irregular and the ribs are oar shaped. Phalanges are shortened and trapezoidal in shape.

At the time of designation, mucopolysaccharidosis type VII affected approximately 0.001 in 10,000 people in the European Union (EU)\*. This is equivalent to a total of around 50 people, and is below the ceiling for orphan designation, which is 5 people in 10,000.

New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood (plasma) of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

Therefore it is the goal of the study to identify and validate a new biochemical marker from the plasma of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Developmental Delay Skeletal Abnormalities Hepatomegaly Splenomegaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation

Patients with Sly disease or high-grade suspicion for Sly disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent will be obtained from the parents before any study related procedures
* Patients of both genders older than 2 months
* The patient has a diagnosis of Sly disease or a high-grade suspicion for Sly disease

Positive family anamnesis for Sly disease

Developmental delay and/or progressive mental deterioration

Skeletal abnormalities

Hepatomegaly

Splenomegaly

Exclusion Criteria

* No Informed consent from the parents before any study related procedures.
* Patients of both genders younger than 2 months
* No diagnosis of Sly disease or no valid criteria for profound suspicion of Sly disease

Minimum Eligible Age

2 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No